BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Immunogen (IMGN): Investing in antibody technology]]>http://www.bloggingstocks.com/2009/07/14/immunogen-imgn-investing-in-antibody-technology/http://www.bloggingstocks.com/2009/07/14/immunogen-imgn-investing-in-antibody-technology/http://www.bloggingstocks.com/2009/07/14/immunogen-imgn-investing-in-antibody-technology/#commentsFiled under: , ,

"How does one go about investing in the antibody space?" asks biotech specialist John McCamant. In The Medical Technology Stock Letter, he eyes Immunogen (NASDAQ: IMGN), and offers an in-depth report for biotech-savvy readers.

"As background, T-DM1 is a second generation Herceptin that may even exceed the original in sales because the armed antibody has been more potent to date by showing effectiveness in mBC patients who have failed either Herceptin or Tykerb.

"The company will continue to benefit from Genetech's extensive antibody experience as they continue to run all development for Immunogen's T-DM1.

Continue reading Immunogen (IMGN): Investing in antibody technology

Immunogen (IMGN): Investing in antibody technology originally appeared on BloggingStocks on Tue, 14 Jul 2009 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>antibody stocksbiotech stocksbiotechnologyBiotechStocksdrug developmentdrug researchDrugDevelopmentDrugResearchherceptinimgnimmunogenjohn mccamantJohnMccamantmedical technology stock letterMedicalTechnologyStockLettersteven halpernStevenHalpernthestockadvisors.comTue, 14 Jul 2009 12:00:00 EST